Listar INIBIC-VC - Artigos por autor "Balboa-Barreiro, Vanesa"
Mostrando ítems 1-6 de 6
-
Clinical experience with the integrase inhibitors Dolutegravir and Elvitegravir in HIV-infected patients: efficacy, safety and tolerance
Cid-Silva, Purificación; Llibre, Josep M.; Fernández-Bargiela, Noelia; Margusino-Framiñán, Luis; Balboa-Barreiro, Vanesa; Pernas, Berta; Martín-Herranz, Isabel; Castro-Iglesias, Ángeles; Poveda, Eva (Wiley, 2017-07-16)[Abstract] Two integrase inhibitors (INSTIs), dolutegravir (DTG) and elvitegravir/cobicistat (EVG/COBI), have joined recently the pharmacotherapy arsenal against HIV. This study evaluated the efficacy and tolerability of ... -
Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study
Fernández-Bargiela, Noelia; Rotea-Salvo, Sandra; Margusino-Framiñán, Luis; Balboa-Barreiro, Vanesa; Martín-Herranz, Isabel; Castro-Iglesias, Ángeles; Mena-De-Cea, Álvaro; López-Calvo, Soledad; Vázquez-Rodríguez, Pilar; Míguez-Rey, Enrique; Cid-Silva, Purificación (BMJ, 2020-10-13)[Abstract] Objectives: Despite the high efficacy of antiretroviral treatment, no drug is free from adverse events (AEs). Efavirenz (EFV) and dolutegravir (DTG) are antiretroviral drugs for which neuropsychiatric adverse ... -
Late HIV Diagnosis but Earlier Antiretroviral Treatment Initiation in Northwest Spain: Impact of Current Treatment Guidelines
Cid-Silva, Purificación; Margusino-Framiñán, Luis; Balboa-Barreiro, Vanesa; Pernas, Berta; Mena, Álvaro; Martín-Herranz, Isabel; Castro-Iglesias, Ángeles; Poveda, Eva (Sage, 2019-01-10)[Abstract] Background: Current HIV treatment guidelines recommend antiretroviral treatment (ART) initiation for all HIV-infected individuals regardless of CD4 count. This study evaluates the immunological and virological ... -
Plasma mitochondrial DNA levels are inversely associated with HIV-RNA levels and directly with CD4 counts: potential role as a biomarker of HIV replication
Pernas, Berta; Rego-Pérez, Ignacio; Tabernilla, Andrés; Balboa-Barreiro, Vanesa; Relaño, Sara; Grandal, Marta; Crespo, Manuel; Mena, Álvaro; Castro-Iglesias, Ángeles; Blanco García, Francisco J; Poveda, Eva (Oxford, 2017-08-31)[Abstract] Objectives. To evaluate plasma mitochondrial DNA (mtDNA) levels among HIV-infected patients and its potential role as a biomarker of residual viral replication. Methods. HIV-infected patients on follow-up at a ... -
Renal profile of patients treated with elvitegravir/ cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort
Rotea-Salvo, Sandra; Martínez-Pradeda, Alejandro; Fernández-Oliveira, Carla; Giménez-Arufe, Víctor; Balboa-Barreiro, Vanesa; Margusino-Framiñán, Luis; Mena-De-Cea, Álvaro; Vázquez-Rodríguez, Pilar; Castro-Iglesias, Ángeles; López-Calvo, Soledad; Martín-Herranz, Isabel; Míguez-Rey, Enrique; Cid-Silva, Purificación (BMJ, 2021-10-14)[Abstract] Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (EVG/c/FTC/TAF) and dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) are currently available for HIV patients. Objectives: This study evaluated ... -
Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV‐infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine
Cid-Silva, Purificación; Fernández-Bargiela, Noelia; Margusino-Framiñán, Luis; Balboa-Barreiro, Vanesa; Mena, Álvaro; López-Calvo, Soledad; Vázquez-Rodríguez, Pilar; Martín-Herranz, Isabel; Míguez-Rey, Martín; Poveda, Eva; Castro-Iglesias, Ángeles (Wiley, 2018-11-02)[Abstract] Two elvitegravir/cobicistat‐based therapies combined with emtricitabine/tenofovir disoproxil fumarate (EVG/c/FTC/TDF) or emtricitabine/tenofovir alafenamide fumarate (EVG/c/FTC/TAF) are currently available for ...